Caris Life Sciences, Inc. CAI

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $812.03M · Filed Mar 3, 2026

Caris Life Sciences, Inc. (CAI) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $812.0 million and a net loss of $68.1 million. Free cash flow was $66.9 million. As of Jun 30, 2026 it held $102.2 million in cash and investments and $452.4 million in total debt.

Revenue (TTM)
$989.61M
Net income (TTM)
$105.14M
Operating cash flow (TTM)
$168.56M
Free cash flow (TTM)
$123.96M
EPS (TTM)
$0.37
Dividend per share
None
Shares outstanding
282.58M
Net cash
$-350.20M
as of Jun 30, 2026
Operating margin
15.5%
FY 2026

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
CAI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
TX
Headquarters
Irving, TX
SEC filer status
, Emerging growth company
SEC CIK
2019410

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$812.0M
Operating income
$45.1M
Net income
-$68.1M
Diluted EPS
-$3.22
Operating cash flow
$83.2M
Free cash flow
$66.9M
Total assets
$1.1B
Total liabilities
$548.4M
Stockholders' equity
$577.3M
Cash and investments
$798.6M
Total debt
$428.2M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations
 Nov 4, 2026 Nov 4, 2026
8-K Current report
Regulation FD disclosure
 Sep 14, 2026 Sep 14, 2026
10-Q Quarterly report Aug 5, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 5, 2026 Aug 5, 2026
8-K Current report
Shareholder vote results
 Jun 5, 2026 Jun 4, 2026

All 133 Caris Life Sciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.